OBESTIN-30 Drug Patent Profile
Which patents cover Obestin-30, and what generic alternatives are available?
Obestin-30 is a drug marketed by Ferndale Labs and is included in one NDA.
The generic ingredient in OBESTIN-30 is phentermine hydrochloride. There is one drug master file entry for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the phentermine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Obestin-30
A generic version of OBESTIN-30 was approved as phentermine hydrochloride by ELITE LABS INC on May 30th, 1997.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OBESTIN-30?
- What are the global sales for OBESTIN-30?
- What is Average Wholesale Price for OBESTIN-30?
Summary for OBESTIN-30
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 34 |
| Patent Applications: | 1,097 |
| DailyMed Link: | OBESTIN-30 at DailyMed |
US Patents and Regulatory Information for OBESTIN-30
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferndale Labs | OBESTIN-30 | phentermine hydrochloride | CAPSULE;ORAL | 087144-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
